01.05.2019 • NewsElaine BurridgeGivaudan

Givaudan Buys AMSilk’s Cosmetics Business

“The acquisition of the cosmetics business of AMSilk fits very well our long...
“The acquisition of the cosmetics business of AMSilk fits very well our long term strategy for Active Beauty,” said. Maurizio Volpi, president of Givaudan’s Fragrance division

Swiss flavors, fragrances and active cosmetic ingredients manufacturer Givaudan has agreed to buy the cosmetics business of Germany’s AMSilk. The acquisition fits with Givaudan’s aim – part of its 2020 strategy – to become a major player in the fast-growing active cosmetic ingredients market.

Headquartered near Munich, AMSilk is an industrial supplier of synthetic silk biopolymers, which can be used in a broad range of applications across categories such as haircare and skincare. AMSilk has filed 10 patents for the use of biopolymers in cosmetic applications.

 “The acquisition of the cosmetics business of AMSilk fits very well our long term strategy for Active Beauty,” said. Maurizio Volpi, president of Givaudan’s Fragrance division. “It offers an expanded portfolio of natural and bio-sourced products supported by a strong research and development biotechnology platform to drive future development and innovation in the active cosmetic ingredients space.”

Laurent Bourdeau, head of Givaudan’s Active Beauty business, added that AMSilk’s unique technology will allow it to enlarge its product portfolio by developing bespoke polypeptides, also aligning with the company’s ambition to meet growing consumer demand for ‘clean beauty’ products.

Givaudan has not revealed financial details of the deal although said it would fund the purchase from its existing resources.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.